Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.
